Navigation Links
One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org
Date:12/30/2008

Today, iGuard.org, a free and secure medication monitoring service, registered its one-millionth member just 14 months after its launch last year. iGuard.org’s rapid growth highlights the growing trend toward patients taking a more active role in managing their own healthcare.

PRINCETON, N.J. (Business Wire EON) December 30, 2008 -- Helping Patients and Physicians

"Despite enormous investment of time and money in healthcare information technology, patients don't feel confident that the healthcare system is watching out for them," said Hugo Stephenson, MD, iGuard.org's founder. "iGuard.org is a really simple service. With most Americans getting their prescriptions from many different doctors, iGuard.org enables patients to register their medications for monitoring and sends them customized email drug safety reports, safety alerts and recalls from a pharmacist as new and personally relevant information emerges."

Barbara Munroe of Phoenix, Ariz. is an iGuard.org member who has epilepsy and takes numerous medications. "After wasting away for a year with no energy, I registered all my medicines on iGuard.org," said Munroe. "To my surprise, I soon received an alert about an interaction between Paxil and another medication I'm taking, Zonegran. Since deleting Paxil from my medications my energy has soared. Without iGuard.org's information, I would still be on the couch -- or worse. It has saved my life."

The iGuard.org Service

iGuard.org maintains an up-to-date database of drug-drug and drug-disease interactions, including feeds from the U.S. Food and Drug Administration (FDA) and major drug manufacturers, to provide users with personalized drug safety reports, safety alerts and product recalls by email. Since iGuard.org pharmacists write and review all alerts for a consumer audience, patients receive understandable, actionable, timely information that they can discuss with their doctors.

Paul Seligman, M.D., M.P.H., Associate Director for Safety Policy and Communication at the FDA, said, "Communicating safety information in a timely fashion is important to all those whoweigh the benefits and risks aboutthe appropriate use of a medicine. Providing this information is a shared responsibility of many in the healthcare system. iGuard.org now provides such a source for this information."

iGuard.org is Different from Other Drug Information Services

Although patients today have access to an enormous set of tools for getting information about their health, iGuard.org is the only service that:

helps patients identify which drugs pose the greatest risk using a personalized, color-coded, drug safety rating system; detects potential interactions between drugs and diseases as well as interactions between drugs – recognizing that drug-disease interactions (e.g., Viagra and heart disease, birth control pills and smoking) are the highest cause of death and disability associated with medication use; communicates emerging product recalls (which outnumber alerts by four to one) as well as safety notifications and FDA advisories; avoids bombarding patients with irrelevant communications by ensuring that drug-specific messages are sent only to those users to whom they apply; ensures that communications are actionable and easy to understand by having a pharmacist review and update FDA / drug company alerts for the consumer audience; allows patients to have their doctor copied on their communications; is funded by medical research, not by advertising, which helps improve medicines. Helping the Scientific Community

iGuard.org connects patients with researchers interested in learning more about how drugs work. iGuard has already helped researchers to document real world rates of side effects for common medications such as statins and antidepressants, and to discover potential interactions between prescription and over-the-counter medications. "Connecting real patients in the real world with drug researchers allows us to learn about medicines much faster," Dr. Stephenson said.

About iGuard.org

iGuard.org, headquartered in Princeton, N.J., is a free and secure source of information for registered users who want to get informed, stay informed and share feedback about their medications. It has received critical support from patient advocacy groups concerned by the large number of patients affected by serious, preventable adverse drug interactions. It offers balanced and timely information to help patients manage their healthcare for themselves or loved ones.

Registration is free online at iGuard.org, or through its partners including the Institute for Safe Medication Practices (www.consumermedsafety.org), participating e-prescribing physicians (www.allscripts.com) and select pharmacies.

Read the full story at http://www.prweb.com/releases/drug_safety/safety_alerts/prweb1807844.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org 
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: